UBX1325

· Unity Biotechnology, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for UBX1325, covering 2024-05-16 to 2024-08-07. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION) [Phase 2]

See pricing